Crypto prices
Loading prices…
CoinGecko · USD · 24h
News section

Business — Page 97

Amgen Reports 58% Lower Death Hazard in Lung Cancer Trial

Median overall survival was 21.1 months with tarlatamab and durvalumab, compared with 12.7 months with durvalumab alone. The trial tested the combination as maintenance therapy after initial treatment.

Oct 24, 20262 min read
Loading…